Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
P/E ratio for Nuvalent, Inc. (NUVL)
P/E ratio as of 2023: -33.95
According to Nuvalent, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -33.95. At the end of 2022 the company had a P/E ratio of -20.17.
P/E ratio history for Nuvalent, Inc. from 2019 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -33.95 |
| 2022 | -20.17 |
| 2021 | -19.85 |
| 2020 | -62.20 |
| 2019 | -76.66 |